Abstract | PURPOSE: METHODS AND MATERIALS: A total of 55 subjects undergoing total body irradiation (TBI)-HSCT were enrolled in this randomized controlled trial. Captopril or identical placebo was started at engraftment and continued as tolerated until 1 year after HSCT. RESULTS: The baseline serum creatinine and calculated glomerular filtration rate (GFR) did not differ between groups. The 1-year serum creatinine level was lower and the GFR higher in the captopril compared with the placebo group (p = 0.07 for GFR). Patient survival was higher in the captopril compared with the placebo group, but this was also not statistically significant (p = 0.09). In study subjects who received the study drug for more than 2 months, the 1-year calculated GFRs were 92 mL/min and 80 mL/min, for the captopril and placebo groups, respectively (p = 0.1). There was no adverse effect on hematologic outcome. CONCLUSIONS:
|
Authors | Eric P Cohen, Amy A Irving, William R Drobyski, John P Klein, Jakob Passweg, Julie-An M Talano, Mark B Juckett, John E Moulder |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 70
Issue 5
Pg. 1546-51
(Apr 01 2008)
ISSN: 0360-3016 [Print] United States |
PMID | 18029109
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Captopril
- Creatinine
|
Topics |
- Adolescent
- Adult
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Captopril
(therapeutic use)
- Child
- Creatinine
(blood)
- Glomerular Filtration Rate
- Hematopoietic Stem Cell Transplantation
- Humans
- Kidney Failure, Chronic
(drug therapy, etiology)
- Prospective Studies
- Statistics, Nonparametric
- Whole-Body Irradiation
(adverse effects)
|